GGrantIndex
← Search

PHASE II TRIAL OF INS365 IN ADULT/PEDIATRIC CF PATIENTS

$0M01FY2000RRNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Abstract

INS 365 is a new molecule under study as an inhaled medication to impreve chloride and water transport and lung mucus clearance. It may also increase mucus clearance by increasing the rate at which the cilia (little hair-like fibers lining the airways) beat to push the mucus out. The purpose of this study is to evaluate the safety of a single dose of INS365 delivered by inhalation from a nebulizer to adults and children with Cystic Fibrosis. The highest dose that can be tolerated will be determined. The effect of INS365 on the amount of sputum produced will also be measured.

View original record on NIH RePORTER →